Holmes C F, Tonks N K, Major H, Cohen P
Biochim Biophys Acta. 1987 Jul 6;929(2):208-19. doi: 10.1016/0167-4889(87)90178-9.
A new procedure has been developed for identifying phosphoserine residues in proteins, and is used to analyse the in vivo phosphorylation state of inhibitor-2. The method employs reverse-phase liquid chromatography to resolve phosphorylated and dephosphorylated forms of peptides and fast-atom bombardment mass spectrometry (FABMS) to identify phosphorylated derivatives. The positions of phosphorylation sites within peptides are located by gas-phase sequencer analysis after conversion of phosphoserine residues to S-ethylcysteine. The phosphorylation sites on inhibitor-2 were identified as serines-86, -120 and -121, the three residues phosphorylated in vitro by casein kinase-II. Serine-86 was phosphorylated to 0.7 mol/mol and serines-120 and -121 each to 0.3 mol/mol. These values were not altered significantly by intravenous injection of adrenalin or insulin. No phosphate was present in the region comprising residues 1-49, even after injection of adrenalin, demonstrating that inhibitor-2 is not a substrate for cyclic AMP-dependent protein kinase in vivo. The absence of phosphotyrosine also indicated that inhibitor-2 is not a physiological substrate for the insulin receptor. Surprisingly, no phosphate was present at threonine-72, the residue phosphorylated in vitro by glycogen synthase kinase-3, after injection of either propranolol, adrenalin or insulin. The implications of this finding for the in vivo activation of protein phosphatase 1I (the 1:1 complex between inhibitor-2 and the catalytic subunit of protein phosphatase-1) are discussed. FABMS analysis of inhibitor-2 confirmed the accuracy of the primary structure reported previously, and showed that the only post-translational modifications were an N-acetyl moiety and the three phosphoserine residues. FABMS also demonstrated the presence of an additional serine residue at the C-terminus, and showed that 50% of isolated inhibitor-2 molecules lack the C-terminal Ser-Ser dipeptide.
已开发出一种用于鉴定蛋白质中磷酸丝氨酸残基的新方法,并用于分析抑制剂-2的体内磷酸化状态。该方法采用反相液相色谱法分离肽的磷酸化和去磷酸化形式,并使用快原子轰击质谱法(FABMS)鉴定磷酸化衍生物。在将磷酸丝氨酸残基转化为S-乙基半胱氨酸后,通过气相测序仪分析确定肽内磷酸化位点的位置。抑制剂-2上的磷酸化位点被确定为丝氨酸-86、-120和-121,这三个残基在体外被酪蛋白激酶-II磷酸化。丝氨酸-86的磷酸化程度为0.7摩尔/摩尔,丝氨酸-120和-121的磷酸化程度均为0.3摩尔/摩尔。静脉注射肾上腺素或胰岛素后,这些值没有明显改变。即使注射肾上腺素后,在包含残基1-49的区域也没有磷酸盐存在,这表明抑制剂-2在体内不是环磷酸腺苷依赖性蛋白激酶的底物。磷酸酪氨酸的缺失也表明抑制剂-2不是胰岛素受体的生理底物。令人惊讶的是,在注射普萘洛尔、肾上腺素或胰岛素后,苏氨酸-72(在体外被糖原合酶激酶-3磷酸化的残基)处没有磷酸盐存在。讨论了这一发现对蛋白磷酸酶1I(抑制剂-2与蛋白磷酸酶-1催化亚基之间的1:1复合物)体内激活的影响。抑制剂-2的FABMS分析证实了先前报道的一级结构的准确性,并表明唯一的翻译后修饰是一个N-乙酰基部分和三个磷酸丝氨酸残基。FABMS还证明在C末端存在一个额外的丝氨酸残基,并表明50%的分离的抑制剂-